January 9, 2017
Ipsen will gain exclusive commercialization rights for the current and potential future of ONIVYDE indications in the U.S. ONIVYDE is an FDA-approved and clinically differentiated product for treating metastatic pancreatic cancer in adult patients. The transaction also includes the commercial and manufacturing infrastructure of Merrimack, and generic doxorubicin HCl liposome injection. The transaction represents a unique opportunity and a strong strategic fit for Ipsen.
Furthermore, there are significant commercial synergies to be realized by integrating the ONIVYDE franchise with the existing Ipsen U.S. oncology commercial infrastructure, which has strong expertise and a proven track record with Somatuline®. Hence, this transaction strengthens the Oncology franchise of Ipsen and accelerates both its near- and long-term profitability and growth trajectory.
“The acquisition of ONIVYDE represents a compelling strategic opportunity to further strengthen Ipsen’s oncology portfolio while leveraging our U.S. infrastructure and creating meaningful potential incremental growth and profitability. Pancreatic cancer is now the third leading cause of cancer-related deaths. It is an area that has had many drug failures and very few FDA approvals over the past two decades. For the tens of thousands of patients living with pancreatic cancer in the U.S. who have received prior treatment with gemcitabine, ONIVYDE represents an important, differentiated innovation, given its proven overall survival benefit in an area of high unmet medical need with few approved therapies,” said David Meek, CEO of Ipsen.
Cynthia Schwalm, Executive Vice President, North America Commercial Operations, Ipsen, said: “ONIVYDE is a landmark, recently approved therapeutic option for metastatic pancreatic cancer. Since the launch in the fourth quarter of 2015, many patients have already benefitted from ONIVYDE. Based on our track record of successfully bringing oncology products to patients, we are confident in our ability to leverage our operational and clinical development capabilities, and experienced commercial and medical affairs teams to ensure eligible patients have access to ONIVYDE in the U.S.”